Trude holds a Global Executive MBA and a Master of Business and Economics degree, both from BI, Norwegian Business School, Norway. Trude has a proven track record of accomplishments with more than 20 years of expertise in MedTech, Biotech and Pharmaceutical industry at Global, European and National levels within alliance management, business development, building corporate and brand strategies, new product launches, and sales development for companies such as Pfizer, UCB, and AstraZeneca. Prior to joining RESPINOR, Trude served as Global Director of Business Development and Alliance Management for Photocure, in Norway. She has been Chief Business Officer of RESPINOR since April 2018 and the CEO since May 2019.

Geir holds a Ph.D. in Medical Image Analysis, from the Norwegian University of Science and Technology (NTNU), Trondheim, and an MSc in Software Engineering, from NTH, Trondheim, Norway. Geir has more than 20 years of experience in the healthcare industry. Geir spent 15 years at Nycomed Amersham/GE Healthcare as  Director Technology collaboration/Technology leader, working with MRI, CT, optical imaging, and ultrasound technology. Geir has experience in medical device development, including clinical, regulatory, and QA experience. Prior to joining RESPINOR, Geir served as Technology Leader at Mentis Cura in Norway. He has been Director QA&RA of RESPINOR since September 2020.

Marit holds an MSc in Human Movement Science from the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway.  She had an internship in France working on a pilot project testing an already CE marked medical device. During her studies, she worked as a research assistant at the Faculty of Medicine and Health at NTNU. She has been Clinical Research Officer of RESPINOR since June 2019 and  Clinical Affairs Manager since January 2020.

Magdalena holds a M.Sc in Finance from the London School of Economics and a M.Sc in Business Administration and Economics from the Gothenburg School of Economics. Magdalena has 30 years of experience from a multitude of roles within business development, strategy, and finance, the past 12 years within the pharma/biotech sector.  She has a proven track record from leading innovation and commercialization processes, including international partnering/licensing, new market entrance, supply chain management, and new venture creation. Previous positions include Director of BD in Weifa. Prior to joining RESPINOR, Magdalena served as  Business Development and Licensing Executive in Inven2. She has been Director Business Development of RESPINOR since April 2022.

Håkon holds an MSc in Applied  Computer and Information Technology (ACIT): Biomedical Engineering and AI (alt.) and a BSc in Electrical Engineering and Information Technology: Medical Technology from OsloMet, Norway. During the studies he has gained experience with non-invasive technologies to monitor physiological processes, such as designing a wearable device of a prototype for a novel glucose monitor based on doppler ultrasound and utilizing optical methods to monitor haemodynamic response in active neuronal tissue. He worked as a lab engineer in the university’s electronics lab next to the studies. Since September 2022 he has worked as Electronics Engineer at RESPINOR.

Magnus holds a MSc in Economics from the Norwegian School of Economics, Bergen.

He has been working with BDOs Business Services since 2017, and as CFO for hire for life science companies since 2022. For RESPINOR he has been serving as CFO since October 2022

Rafael holds a Ph.D. in Electromagnetism and Fluid Dynamics, from the Institute of Fluid Mechanics (IMFT), Toulouse, France, and an MSc in Mechanical Engineering from INSA, Toulouse, France. Rafael has more than 8 years of experience in non-invasive sensor technology. During his Ph.D., he worked on the monitoring of liquid metal flows using both electromagnetic and ultrasonic technologies. Rafael has experience in digital signal processing, mathematical modeling, data analysis, and statistics. He has been a Signal Processing Engineer at RESPINOR since June 2020

Anders was until recently the CEO of GE Healthcare’s Global Clinical Care Solution business unit with USD 6 billion in sales and over 10,000 employees. The business unit includes Ultrasound, Patient Monitoring, Anesthesia, Ventilation, Diagnostic Cardiology, Maternal Infant Care, Digital Solutions & Service, and a pillar in GE Healthcare.

He has a long career in Health Tech in various roles from start-up, innovation, and market creation to global leadership.  More than 20 years of commercial and executive leadership at GE Healthcare. He took the global Ultrasound business to market leadership through both organic growth, M&A and market creation. Anders has built a fast-paced innovation process launching more than 20 new products every year over the last decade. The last new product added to the portfolio was the handheld Ultrasound Vscan Air™, Time magazine innovation of the year. He is currently BOD of several Medtech and Biotech companies with focus on start-ups. Anders is B.Sc. Biomedical electronics, from the University of Salford, UK

Jan has more than 20 years of experience in various executive roles in the international pharmaceutical industry. He was running the Japan region for GE Healthcare for 10 years – a role including building infrastructure on the ground while optimise the business through Strategic Alliance and JV structures. He had full P&L responsibility for a $130m business. Jan has also been running the global pharma R&D operations in GE Healthcare including a $50m development portfolio and project/portfolio teams in UK, USA and Norway. Jan left GE in Oct 2014 as the President of the 800 employees Norwegian organization. Besides being a board member in RESPINOR, Jan is also Chairman of the board of Mentis Cura AS and Phoenix Solutions AS and board member of Oxy Solutions AS and Spinchip Diagnostics AS.

Lic.oec HSG (MBA) from Hochschule St. Gallen, CH, Director.Aage is today a real-estate and life science investor and the largest shareholder in Respinor. He worked for 10 years as a management consultant and as “Management for Hire” with Asbjørn Habberstad AS in the Nordic countries. He was later Owner and CEO of the largest privately owned importer of agricultural machinery in Norway.

Marco has more than 35 years of experience in various international executive roles in the biopharma industry. He currently serves as Chief Executive Officer at Blue Wave Therapeutics, a private, preclinical stage, radiopharmaceutical company with offices in Switzerland and Norway. Previously he had been Chief Operating Officer at Nordic Nanovector, a public clinical stage company listed on the Oslo Stock Exchange (2014-2021). Prior to joining Nordic Nanovector, Marco served as SVP, Chief Commercial Officer at Shionogi Ltd (2012-2014). From 2009 to 2012, he was Executive Director, Oncology Franchise Head for Amgen International, after leading (2005-2008) the Italian affiliate as Managing Director. Prior to Amgen, Marco held national and global R&D and business roles at Novartis, Searle-Monsanto and Pharmacia. Marco has been Board Chairperson of Phi Pharma, a private Switzerland-based biotech company focusing on the development of peptide drug conjugates. Marco holds a medical degree from the University of Milan and an MBA from Fondazione IDI/Assolombarda. Marco is an Italian citizen, and he currently resides in Italy.

Carl Christian Gilhuus-Moe holds a Ph.D. in clinical biochemistry from Oslo University and has studied business management at the Swedish Institute of Management and Sloan School of Management at MIT (Boston)

He has 25 years of experience from 1997 as a Partner/Senior Advisor to NeoMed Management, making Venture Investments in the Health Care Industry. Prior to this, he had another 25 years of operating experience in the healthcare and life science industry. He was founding President and CEO of Dynal Biotech (now part of Thermo Fisher) 1986 – 1997. He was founding President and CEO of Dynal Biotech (now part of Thermo Fisher) 1985-1997Prior to this, he held a number of management positions at Nycomed (now part of GE Healthcare) most recently, as Senior VP and Head of the Diagnostic Division (1971-1985). During his Venture Partner tenure, he has been a Board member and Chairman to the Board of various healthcare-focused start-up companies in NeoMed’s portfolio, both in Europe and the US. He is currently the Board Chairperson of Bio-Me, a key player in the quickly evolving microbiome field, and a board member of both Cardiaccs and RESPINOR.Dr. Gilhuus-Moe was the founding Chairperson to the Board of health industry cluster: Norway Health Tech 2009 – 2019. He had the same position in Sintef Unimed (the health industry sector of the Norwegian Institute of Technology) 1992 – 2005. Prior to this, he was elected to President of ECCLS (the European Committee for Clinical Laboratory Standards) 1985-1997. Since 2015, he has been a member of the Executive Board of Excite International, a not-for-profit organization of global stakeholders in Health Industry Innovation.

Otto Skolling is currently Chief Business Officer at Asarina Pharma and Nanexa AB. He has more than 25 years within life science industry predominantly within BD, financing, and product development in management positions within Pharmacia Upjohn, Siemens Life support systems, Novozymes and Karolinska development. He has broad board experience from several early-stage life science companies. As a background, Otto has a MSc. in Chemical Engineering from the Royal institute of Technology, Stockholm